Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perinatal/Neonatal Case Presentation
  • Published:

Perinatal/Neonatal Case Presentation

Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine

Journal of Perinatology volume 27, pages 517–518 (2007)Cite this article

Abstract

We describe a full-term infant with failed respiratory effort and decerebrate posturing following in utero exposure to paroxetine. All signs and symptoms associated with the paroxetine exposure were resolved by the second day of life. Upon discharge, the infant revealed a normal neurodevelopmental examination.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Eberhard-Gran M, Eskild A, Opjordsmoen S . Treating mood disorders during pregnancy: safety considerations. Drug Saf 2005; 28(8): 695–706.

    Article  CAS  Google Scholar 

  2. FDA Public Health Advisory. Paroxetine. December 8, 2005 [cited January 12, 2007]. Available from http://www.fda.gov.

  3. Laine K, Heikkinen T, Ekblad U, Kero P . Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60: 720–726.

    Article  CAS  Google Scholar 

  4. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 2372–2383.

    Article  CAS  Google Scholar 

  5. Thormahlen G . Paroxetine use during pregnancy: is it safe? Ann Pharmacother 2006; 40: 1834–1837.

    Article  CAS  Google Scholar 

  6. DOA Specificity Table. Tricyclic Antidepressants.. Biosite Incorporated: San Diego, CA, March 2006.

  7. Gentile S . Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother 2004; 38: 1265–1271.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Centennial Medical Center, Nashville, TN, USA

    K L Murray & K M Miller

  2. Mid-Tennessee Neonatology Associates, Centennial Medical Center, Nashville, TN, USA

    D L Pearson

Authors
  1. K L Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K M Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D L Pearson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K L Murray.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murray, K., Miller, K. & Pearson, D. Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine. J Perinatol 27, 517–518 (2007). https://doi.org/10.1038/sj.jp.7211772

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211772

Keywords

This article is cited by

Search

Advanced search

Quick links